Experimental Lymph-Node injection for skin cancer trial halted early

NCT ID NCT05393713

Terminated Disease control Sponsor: Mayo Clinic Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested whether giving the immunotherapy drug STI-3031 directly into the lymph nodes or vessels (using a special device) is safe for people with in-transit melanoma, a type of skin cancer that spreads through lymph channels. Only 3 people took part before the study was stopped early. The goal was to find the best dose and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: STI-3031 (anti-PD-L1 antibody)
What this could lead to: If successful, this approach could offer a more targeted way to treat in-transit melanoma with fewer side effects than standard immunotherapy.
What could go wrong: This was a very early (Phase 1) trial that was terminated after only 3 participants, so we have very little data on safety or effectiveness. The results may not apply to other patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLINICAL STAGE III CUTANEOUS MELANOMA AJCC V8 MELANOMA METASTATIC MELANOMA RECURRENT METASTATIC MELANOMA

Experimental Lymph-Node injection for skin cancer trial halted early

Summary

What this could mean

Get notified about this study

Conditions

As listed by the trial registrant

Contacts and locations

Locations

More trials for these conditions